# Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

> **NCT06316076** · PHASE1 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** CD19-CAR-DNT cells

## Key facts

- **NCT ID:** NCT06316076
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2024-06
- **Final completion:** 2026-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06316076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06316076, "Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06316076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*